Discovery of highly potent, nonsteroidal 17β-hydroxysteroid dehydrogenase type 1 inhibitors by virtual high-throughput screening

17β-Hydroxysteroid dehydrogenase type 1 (17β-HSD1) catalyzes the formation of the potent proliferation-stimulating hormone estradiol, and it is thus involved in the development of hormone-dependent breast cancer. Due to its high substrate specificity and the known relationships between its overexpression and disease incidence, 17β-HSD1 is considered an attractive target for drug development. Here, we have used structure-based virtual high-throughput screening to successfully identify potent nonsteroidal 17β-HSD1 inhibitors. Computational screening of a drug-like database containing 13 million compounds identified hits with a 2-benzylidenebenzofuran-3(2H)-one scaffold that we show to be highly potent 17β-HSD1 inhibitors. The most potent in the series, compound 1, showed an IC50 of 45 nM in our 17β-HSD1 inhibition assay, and also showed good selectivity for 17β-HSD1 over 17β-HSD2.

Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slideHighlights► Virtual high-throughput screening was performed in order to discover new nonsteroidal inhibitors of 17β-HSD1. ► Highly potent and selective inhibitors with 2-benzylidenebenzofuran-3(2H)-one scaffold were identified. ► The most potent compound had IC50 value of 45 nM in in vitro 17β-HSD1 inhibition assay.